MCL	mantle cell lymphoma
CAR-T cells	chimeric antigen receptor-T cells
BTKi	Bruton’s tyrosine kinase inhibitor
MAB	monoclonal antibody
ICD	immunoconjugated drug
TCE	T-cell engaging
R/R	relapsed/refractory
NHL	non-Hodgkin lymphoma
COO	cell of origin
MIPI	MCL international prognostic index
MRD	minimal residual disease
ASCT	autologous stem cell transplantation
ORR	overall response rate
CR	complete remission
PFS	progression-free survival
OS	overall survival
DOR	duration of response
BR	Bendamustine-rituximab
BAC	Bendamustine-cytarabine-rituximab
R-CHOP	rituximab-prednisone-doxorubicin-vincristine-cyclophosphamide
MTD	maximum tolerated dose
Brexu-cel	Brexucabtagene autoleucel
Liso-cel	Lisocabtagene maraleucel
CLL	chronic lymphocytic leukemia
TLS	tumor lysis syndrome
CRS	cytokine release syndrome
ICANS	immune effector cell-associated neurotoxicity syndrome
ROR1	retinoic acid receptor 1
PD-L1	programmed death-ligand 1
DLBCL	diffuse large B-cell lymphoma
FL	follicular lymphoma